Anzeige
Mehr »
Login
Samstag, 25.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Achtung! Ist das die Krypto-Aktie des Jahres 2024 mit 700% Potential?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DXS0 | ISIN: US17322U2078 | Ticker-Symbol: 47N
Tradegate
23.05.24
19:47 Uhr
0,640 Euro
+0,032
+5,18 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
CITIUS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
CITIUS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,6100,63013:03
0,5940,62424.05.

Aktuelle News zur CITIUS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiTenX Keane Acquisition Receives $67K from Merger Partner Citius Oncology to Push Deadline into June3
DiCitius Pharma's 'Antibiotic Lock' Effective In Patients With Catheter-Associated Bloodstream Infections3
DiWhy Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today?4
DiUS STOCKS Nikola, Citius Pharmaceuticals, Full Truck Alliance21
DiCitius gains as late-stage trial for Mino-Lok succeeds1
DiCitius Pharma surges as anti-infective drug succeeds in late-stage study3
DiXFRA 47N: WIEDERAUFNAHME/RESUMPTION168FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
DiCitius Pharma Announce Positive Topline Results For Pivotal Phase 3 Clinical Trial Of Mino-Lok4
DiXFRA 47N: AUSSETZUNG/SUSPENSION86DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCITIUS PHARMAC....
► Artikel lesen
DiCitius Pharmaceuticals, Inc.: Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution53Trial achieves statistically significant primary endpoint (p=0.0006) Secondary endpoint demonstrates statistically significant overall success of Mino-Lok therapy with a greater percentage of patients...
► Artikel lesen
15.05.Citius Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary3
14.05.Citius Pharmaceuticals Non-GAAP EPS of -$0.051
14.05.Citius Pharmaceuticals, Inc. - 8-K, Current Report1
14.05.Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update47Mino-Lok data analysis on track with topline results anticipated this quarter LYMPHIR biologics license application accepted with PDUFA target action date set for August 13, 2024 CRANFORD, N.J....
► Artikel lesen
06.05.TenX Keane Acquisition Files Proxy on Citius Deal2
30.04.Citius Pharmaceuticals, Inc. - 8-K, Current Report2
26.04.Citius Pharmaceuticals to raise $15M through direct offering; shares fall2
11.04.Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma256National Cancer Institute (NCI)-designated research and treatment center City of Hope, in Duarte, CA, to participate in the University of Minnesota (UMN) Masonic Cancer Center's ongoing Phase 1 trial...
► Artikel lesen
05.04.Citius Pharmaceuticals, Inc. - 8-K, Current Report2
18.03.Citius Pharmaceuticals receives FDA acceptance of resubmission for its relapsed lymphoma treatment8
Seite:  Weiter >>
46 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1